Phase I Study of adjuvant chemotherapy for the patients resected pathological stage IA(T1>2cm) Non Small Cell Lung Cancer (SLCG0701)

Phase I Study of adjuvant chemotherapy for the patients resected pathological stage IA(T1>2cm) Non Small Cell Lung Cancer (SLCG0701) - TS-1 for p-stage IA NSCLC(SLCG0701)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006967

Enrollment

Registered

2011-12-27

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Interventions

A:TS-1 day1-28, q2w for one year A:TS-1 day1-14, q1w for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) pathologically proven Non Small Cell Lung Cancer 2) complete resection 3) pathological stage IA (T1>2cm) 4) at least lobectomy, within 4 to 6 weaks after surgery 5) LN dissection (ND2a) 6) no prior anti cancer treatment for thoracic malignancy except for this operation 7) ECOG PS 0-1 8) adequate organ function 9) oral intake 10) Signed informed consent

Exclusion criteria

Exclusion criteria: 1. sever infection, uncontrolled Diabetes Mellitus, and hypertension 2. unstable angina or Myocardial Infarction within 6 months 3. apparent interstitial pneumonitis at chest rentogenogram 4. systemic steroid therapy required 5. uncontrolled cancer 6. Pregnant or expecting woman 7. serious psychiatric illness 8. usaige of other fluorinated pyrimidine drugs 9. Concomitant therapy with flucytocine, phenytoin or Warfarin Potassium

Design outcomes

Primary

Measure	Time frame
drug compliance	—

Countries

Japan

Contacts

Public ContactShinichi Toyooka

Setouchi Lung Cancer Group Okayama University, Cancer and Thoracic Surgery

toyooka@md.okayama-u.ac.jp086-235-7265

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Phase I Study of adjuvant chemotherapy for the patients resected pathological stage IA(T1&gt;2cm) Non Small Cell Lung Cancer (SLCG0701)